Kommentar
Patent Listing Challenges by the Federal Trade Commission
JAMA Internal Medicine · 01.07.2026 · 186 (7) · 801
DOI: 10.1001/jamainternmed.2026.0987 ↗Kurz gefasst
Kommentar in der Zeitschrift JAMA Internal Medicine, erschienen am 01.07.2026. Verfasst von Anna Hung und 1 weiteren Autor:innen. Beteiligte Einrichtung: Editorial Fellow, JAMA Internal Medicine. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Editorial Fellow, JAMA Internal Medicine.
- Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina.
- Duke-Margolis Institute for Health Policy, Durham, North Carolina.
- Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, Durham, North Carolina.
- Associate Editor, JAMA Internal Medicine.
- National Clinician Scholars Program, Yale School of Medicine, New Haven, Connecticut.
Zitieren
APA
Hung, A., & Gross, C. P. (2026). Patent Listing Challenges by the Federal Trade Commission. JAMA Internal Medicine, 186(7), 801. https://doi.org/10.1001/jamainternmed.2026.0987
Vancouver
Hung A, Gross CP. Patent Listing Challenges by the Federal Trade Commission. JAMA Internal Medicine. 2026;186(7):801. doi:10.1001/jamainternmed.2026.0987
BibTeX
@article{Hung2026,
author = {Hung, Anna and Gross, Cary P},
title = {Patent Listing Challenges by the Federal Trade Commission},
journal = {JAMA Internal Medicine},
year = {2026},
volume = {186},
number = {7},
pages = {801},
doi = {10.1001/jamainternmed.2026.0987}
}
EUVIMED